Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gum disease breakthrough? hyaluronic acid gel may rival standard treatment

NCT ID NCT07230522

Disease control Sponsor: Medical University of Sofia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a hyaluronic acid gel (HyaDent BG) works as well as Emdogain, a standard treatment, for repairing bone defects caused by gum disease. Both were used with a bone graft material during surgery. Seventeen adults with advanced periodontitis took part. The goal was to see if the hyaluronic acid could reduce pocket depth, improve gum attachment, and increase bone fill similarly to Emdogain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyaluronic acid gel (HyaDent BG) and enamel matrix proteins (Emdogain)
What this could lead to
If hyaluronic acid works as well as Emdogain, it could offer a simpler, possibly cheaper option to help regrow bone lost to gum disease.
What could go wrong
This is a very small study (17 people) with no blinding, so results may not hold up in larger trials. Gum disease often requires ongoing care, so this is not a permanent fix.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

Mar 2024

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults over the age of 18 diagnosed with periodontal disease-Stage III or IV periodontitis; * Sites with bone defects and a probing pocket depth (PPD) ≥ 6 mm, accompa-nied by bleeding on probing (BoP) at re-evaluation, conducted six weeks after non-surgical periodontal therapy; * Full Mouth Plaque Score (FMPS) \< 20% and Full Mouth Bleeding Score (FMBS) \< 15% prior to surgical treatment; * Good general health with no systemic conditions and no known allergies to materials or medications used in the study. Exclusion Criteria: * Medical conditions contraindicating surgical intervention; * Pregnancy or lactation; * Heavy smokers; * Untreated periodontal disease; * Poor oral hygiene; * Acute infectious lesions in the area of intervention;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrabony periodontal defect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intrabony periodontal defect Periodontal bone loss Periodontitis

Contacts and locations

Locations

  • Departement of Periodontology, Faculty of Dental Medicine, Medical University of Sofia

    Sofia, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.